KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype
International Journal of Molecular Sciences · 20.03.2024 · 25 (6) · 3510
DOI: 10.3390/ijms25063510 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.03.2024. Verfasst von Christopher J Occhiuto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NCI.
Abstract (Originalsprache)
Considerable advances have been made in lung cancer therapies, but there is still an unmet clinical need to improve survival for lung cancer patients. Immunotherapies have improved survival, although only 20–30% of patients respond to these treatments. Interestingly, cancers with mutations in Kelch-like ECH-associated protein 1 (KEAP1), the negative regulator of the nuclear factor erythroid 2-related factor 2 (NRF2) transcription factor, are resistant to immune checkpoint inhibition and correlate with decreased lymphoid cell infiltration. NRF2 is known for promoting an anti-inflammatory phenotype when activated in immune cells, but the study of NRF2 activation in cancer cells has not been adequately assessed. The objective of this study was to determine how lung cancer cells with constitutive NRF2 activity interact with the immune microenvironment to promote cancer progression. To assess, we generated CRISPR-edited mouse lung cancer cell lines by knocking out the KEAP1 or NFE2L2 genes and utilized a publicly available single-cell dataset through the Gene Expression Omnibus to investigate tumor/immune cell interactions. We show here that KEAP1-mutant cancers promote immunosuppression of the tumor microenvironment. Our data suggest KEAP1 deletion is sufficient to alter the secretion of cytokines, increase expression of immune checkpoint markers on cancer cells, and alter recruitment and differential polarization of immunosuppressive macrophages that ultimately lead to T-cell suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
ORCID-Profile: Christopher J Occhiuto, Karen T Liby
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NCI
- DOD Lung Cancer Research Program
- Integrative Pharmacological Sciences Training
Zitieren
APA
Occhiuto, C. J., & Liby, K. T. (2024). KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype. International Journal of Molecular Sciences, 25(6), 3510. https://doi.org/10.3390/ijms25063510
Vancouver
Occhiuto CJ, Liby KT. KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype. International Journal of Molecular Sciences. 2024;25(6):3510. doi:10.3390/ijms25063510
BibTeX
@article{Occhiuto2024,
author = {Occhiuto, Christopher J and Liby, Karen T},
title = {KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3510},
doi = {10.3390/ijms25063510}
}
EUVIMED